Efficacy Study of Two Different Strategies for Restenosis in Sirolimus-Eluting Stents

Inclusion Criteria: * Patients older than age 18 with ischemic symptoms or evidence of myocardial ischemia in the presence of \> 50% re- stenosis after prior implantation of Sirolimus eluting stents in native coronary vessels * Written, informed consent by the patient or her/his legally-authorized representative for participation in the study * In women with childbearing potential a negative pregnancy test is mandatory Exclusion Criteria: * Cardiogenic shock * Acute myocardial infarction within the first 48 hours from symptom onset. * Target lesion located in the left main trunk or bypass graft. * Malignancies or other comorbid conditions (for example severe liver, renal and pancreatic disease) with life expectancy less than 12 months or that may result in protocol non-compliance. * Allergy to antiplatelet therapy, sirolimus, paclitaxel, stainless steel. * Pregnancy (present, suspected or planned) or positive pregnancy test. * Previous enrollment in this trial. * Patient's inability to fully comply with the study protocol.